Table 2.

Relative risks for virologic suppression in adolescents compared to adults

Time of follow-up	Unadjusted		Adjusted for all variables other than adherence †		Completely adjusted ‡
	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P
At 6 months*	0.91 (0.78–1.07)	0.24	0.88 (0.74–1.05)	0.16	0.96 (0.79–1.16)	0.65
At 12 months*	0.74 (0.57–0.95)	0.02	0.65 (0.48–0.90)	0.01	0.74 (0.53–1.03)	0.08
At 18 months*	0.75 (0.56–1.01)	0.06	0.84 (0.60–1.17)	0.31	-	-
At 24 months*	0.70 (0.49–1)	0.05	0.72 (0.49–1.06)	0.10	0.78 (0.53–1.15)	0.22

^*Time is measured in months after HAART initiation.

^†Includes gender, race, baseline CD4, baseline viral load, ART regimen (NNRTI- vs. PI-based), ART initiation before 2003, and number of viral load measurement per patient-months.

^‡Adherence categorized in strata of ≤50%, 51–67%, 67–84%, 85–99% and 100% and baseline variables as described in (†). No adherence data at 18 months.